title: Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia.
abstract: Mastocytosis is an uncommon disorder defined by increased and abnormal mast cells in one or more tissues. Cutaneous mastocytosis (cm) is limited to the skin, with varying degrees of rash, pruritus, and disfigurement. Systemic mastocytosis (sm) typically involves the bone marrow, sometimes in association with other bone marrow disorders, including chronic myelomonocytic leukemia (cmml). Mastocytosis has been associated with somatic mutations in the gene encoding the tyrosine kinase Kit, leading to identification of Kit as a therapeutic target. The Kit inhibitor imatinib mesylate is approved for aggressive sm. We present an unusual patient with disabling pruritus from telangiectasia macularis eruptiva perstans, a subtype of cm, and cmml, but with no evidence of systemic mast cell disease. She was treated with imatinib and experienced marked improvement in her pruritus. Concomitant cm and cmml have not previously been reported, and the present report is the first of successful imatinib therapy in an adult patient with cm.
authors.affiliation: Department of Medicine, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD, U.S.A.
authors.forename: E J
authors.initials: EJ
authors.lastname: Vannorsdall
authors.forename: J A
authors.initials: JA
authors.lastname: Collins
authors.forename: Q C
authors.initials: QC
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: Sarai
authors.forename: M R
authors.initials: MR
authors.lastname: Baer
keywords: Mastocytosis; chronic myelomonocytic leukemia; cutaneous; imatinib; pruritus; tmep; tyrosine kinase inhibitor
references.citation: Hematol Oncol Clin North Am. 2000 Jun;14(3):537-55, vi
references.pmid: 10909039
references.citation: Arch Dermatol. 2011 Aug;147(8):932-40
references.pmid: 21844452
references.citation: Br J Haematol. 2007 Jul;138(1):12-30
references.pmid: 17555444
references.citation: Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1609-14
references.pmid: 9990072
references.citation: US Obstet Gynecol. 2011 Jan 1;6(1):24-34
references.pmid: 21927621
references.citation: J Am Acad Dermatol. 1982 Aug;7(2):215-20
references.pmid: 6957422
references.citation: Am J Hematol. 2010 Dec;85(12):921-5
references.pmid: 21108325
references.citation: Leuk Res. 2011 Sep;35(9):1143-52
references.pmid: 21641642
references.citation: J Am Acad Dermatol. 2000 Nov;43(5 Pt 2):972-4
references.pmid: 11044837
references.citation: J Pathol. 2010 Apr;220(5):586-95
references.pmid: 20112369
references.citation: J Clin Aesthet Dermatol. 2011 Oct;4(10):52-4
references.pmid: 22010057
references.citation: Am J Hematol. 2011 Apr;86(4):362-71
references.pmid: 21442641
references.citation: Dermatology. 2007;214(1):15-20
references.pmid: 17191042
references.citation: Leuk Res. 2001 Jul;25(7):519-28
references.pmid: 11377676
references.citation: Eur J Dermatol. 2002 Mar-Apr;12(2):201-3
references.pmid: 11872425
references.citation: Cancer. 2011 Dec 15;117(24):5439-49
references.pmid: 21692073
references.citation: J Pediatr. 2013 Jan;162(1):205-7
references.pmid: 23069194
references.citation: Mod Pathol. 2009 Jan;22(1):50-7
references.pmid: 19116630
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3906-15
references.pmid: 18559612
references.citation: Blood. 2008 Sep 1;112(5):1655-7
references.pmid: 18567837
references.citation: Int J Dermatol. 2004 Dec;43(12):922-4
references.pmid: 15569020